Your browser is no longer supported. Please, upgrade your browser.
SURF [NASD]
Surface Oncology, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own1.10% Shs Outstand40.01M Perf Week-0.11%
Market Cap365.13M Forward P/E- EPS next Y-0.75 Insider Trans-89.42% Shs Float36.17M Perf Month-18.44%
Income-24.00M PEG- EPS next Q-0.05 Inst Own61.10% Short Float4.50% Perf Quarter14.76%
Sales39.00M P/S9.36 EPS this Y-495.10% Inst Trans-7.66% Short Ratio1.07 Perf Half Y45.72%
Book/sh2.15 P/B4.20 EPS next Y-275.00% ROA-17.10% Target Price- Perf Year177.54%
Cash/sh2.53 P/C3.56 EPS next 5Y- ROE-29.80% 52W Range1.38 - 14.40 Perf YTD-2.38%
Dividend- P/FCF- EPS past 5Y- ROI-88.70% 52W High-38.75% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low539.13% ATR0.88
Employees49 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)37.17 Volatility7.73% 7.93%
OptionableYes Debt/Eq0.17 EPS Q/Q34.90% Profit Margin-61.40% Rel Volume0.92 Prev Close9.02
ShortableYes LT Debt/Eq0.17 Earnings- Payout- Avg Volume1.52M Price8.82
Recom1.70 SMA20-14.01% SMA50-16.36% SMA20015.40% Volume709,966 Change-2.22%
Sep-04-20Initiated H.C. Wainwright Buy $11
Aug-28-20Initiated Wedbush Outperform $12
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
Mar-02-21 12:30PM  
Feb-24-21 07:00AM  
Feb-23-21 07:25AM  
Feb-22-21 06:21AM  
Feb-11-21 07:00AM  
Jan-19-21 03:25PM  
Jan-13-21 08:39AM  
Jan-11-21 06:00AM  
Dec-22-20 12:20PM  
04:37AM  
Dec-17-20 03:35PM  
08:10AM  
06:55AM  
Dec-14-20 07:07AM  
Dec-07-20 08:29AM  
Nov-25-20 07:00AM  
Nov-15-20 08:39AM  
06:57AM  
Nov-13-20 07:05AM  
Nov-11-20 07:00AM  
Nov-10-20 06:20AM  
Nov-09-20 04:25PM  
09:00AM  
Nov-05-20 09:43AM  
Oct-26-20 04:05PM  
Oct-20-20 01:03PM  
Oct-19-20 12:32PM  
Oct-12-20 03:41PM  
Sep-16-20 05:05PM  
Sep-15-20 07:23AM  
Sep-11-20 03:00PM  
Sep-09-20 01:15PM  
Sep-04-20 09:38AM  
Sep-02-20 08:52AM  
Aug-28-20 10:16AM  
Aug-19-20 01:56PM  
Aug-11-20 06:30AM  
Aug-05-20 11:59AM  
Jun-12-20 09:45AM  
Jun-10-20 08:12PM  
May-28-20 04:10PM  
May-20-20 11:28AM  
07:15AM  
07:05AM  
May-15-20 11:46AM  
07:30AM  
May-14-20 07:30AM  
May-13-20 08:00AM  
May-12-20 06:20AM  
May-07-20 12:30PM  
Apr-23-20 08:00AM  
Mar-17-20 08:00AM  
Mar-12-20 10:39AM  
Mar-10-20 06:20AM  
Mar-06-20 11:30AM  
Feb-25-20 04:05PM  
Feb-19-20 11:30AM  
Feb-04-20 06:58AM  
Jan-28-20 07:12AM  
Jan-27-20 04:05PM  
Dec-23-19 10:24AM  
Dec-09-19 05:45PM  
Nov-26-19 11:07AM  
08:00AM  
Nov-25-19 08:00AM  
Nov-18-19 06:30AM  
Nov-12-19 07:45AM  
06:30AM  
Nov-07-19 08:00AM  
Oct-26-19 06:25PM  
Oct-07-19 07:00AM  
Sep-23-19 12:50PM  
Sep-18-19 05:55PM  
Sep-17-19 05:25PM  
Sep-03-19 04:05PM  
01:45PM  
07:00AM  
Aug-28-19 10:45AM  
Aug-27-19 08:00AM  
Aug-21-19 08:45PM  
Aug-20-19 01:15PM  
Aug-15-19 11:20PM  
Aug-14-19 08:55PM  
Aug-12-19 06:20PM  
Aug-08-19 09:05PM  
Aug-07-19 10:30PM  
09:30PM  
10:07AM  
09:05AM  
06:05AM  
Aug-06-19 05:52PM  
12:55PM  
10:30AM  
Aug-03-19 11:05AM  
Aug-01-19 01:15PM  
Jul-30-19 09:25PM  
Jul-29-19 01:15PM  
Jul-26-19 11:40PM  
Jul-25-19 03:09PM  
Jun-07-19 12:00PM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSS ROBERT W.Chief Medical OfficerFeb 16Sale11.351,00011,35088,000Feb 18 08:00 PM
Goater JeffChief Executive OfficerFeb 08Option Exercise3.182,5007,950264,500Feb 09 08:00 PM
FEES JESSICASee RemarksFeb 08Sale12.451,50018,67599,183Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 08Sale12.502,50031,250262,000Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 01Option Exercise3.182,5007,950264,500Feb 03 08:00 PM
FEES JESSICASee RemarksFeb 01Sale11.191,50016,785100,683Feb 03 08:00 PM
Goater JeffChief Executive OfficerFeb 01Sale10.692,50026,718262,000Feb 03 08:00 PM
Goater JeffChief Executive OfficerJan 19Option Exercise3.185,00015,900267,000Jan 21 08:17 PM
Goater JeffChief Executive OfficerJan 19Sale13.005,00065,000262,000Jan 21 08:17 PM
ROSS ROBERT W.Chief Medical OfficerJan 15Sale12.252,00024,50089,000Jan 15 08:00 PM
ROSS ROBERT W.Chief Medical OfficerJan 14Sale11.957,00083,65091,000Jan 15 08:00 PM
Atlas Venture Fund IX, L.P.10% OwnerDec 17Sale18.101,700,00030,770,0002,945,453Dec 21 01:32 PM
GRAYZEL DAVID S.DirectorDec 17Sale18.101,700,00030,770,0002,945,453Dec 21 01:32 PM
ROSS ROBERT W.Chief Medical OfficerDec 15Sale10.481,00010,48098,000Dec 17 08:00 PM
ROSS ROBERT W.Chief Medical OfficerDec 11Sale10.051,40514,12099,000Dec 15 08:00 PM
FEES JESSICASee RemarksNov 25Option Exercise5.061,3836,996102,183Nov 27 08:00 PM
ROSS ROBERT W.Chief Medical OfficerNov 11Sale10.055955,980100,405Nov 13 08:00 PM
FEES JESSICASee RemarksOct 28Option Exercise4.144,89520,262100,800Oct 30 08:30 PM
ROSS ROBERT W.Chief Medical OfficerOct 14Sale10.054,00040,200101,000Oct 16 08:02 PM
EcoR1 Capital, LLC10% OwnerSep 01Sale7.14332,7802,376,6814,701,081Sep 03 04:17 PM
New Enterprise Associates 14, 10% OwnerMay 20Sale3.66420,0001,535,5622,892,877May 22 04:56 PM